利巴巴鲁姆多糖可通过恢复肠道屏障功能和调节肠道微生物群来缓解DSS诱导的慢性性结肠炎
Zhi-Yu Li1,2, Lan-Hui Lin2,3, He-Jun Liang2,3
1Department of Gastroenterology, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China.
Annals of medicine
|December 7, 2023
概括
草甘多糖 (LBP) 通过改善肠道屏障功能和微生物群,减轻小鼠慢性性结肠炎 (UC). 低血压调节炎性细胞因子,增强有益细菌,增加短链脂肪酸 (SCFA).
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 微生物学 微生物学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,其特点是肠道屏障功能障碍和肠道功能障碍.
- 硫酸德克斯 (DSS) 诱导的小鼠结肠炎是研究UC病原和治疗干预措施的相关模型.
- 巴巴多糖 (LBP) 是一种具有潜在抗炎和免疫调节功能的生物活性化合物.
研究的目的:
- 在慢性性结肠炎 (UC) 的小鼠模型中研究Lycium barbarum多糖 (LBP) 对肠道屏障功能和微生物群的保护作用.
- 阐明LBP改善DSS诱导的大肠炎的潜在机制,重点关注炎症性细胞因子调节,紧结蛋白表达和肠道微生物组成.
主要方法:
- 在C57BL/6J雄性小鼠中,使用2%硫酸 (DSS) 不连续3周诱导慢性性结肠炎 (UC).
- 在整个8周的研究期间,小鼠接受了1%干重量的Lycium barbarum多糖 (LBP) 治疗.
- 结肠组织和内含量被收集用于分析组织病理学,炎症标记物,紧结蛋白,肠道微生物群组成和短链脂肪酸 (SCFA).
主要成果:
- 腰痛治疗显著改善了结肠炎的症状,包括体重增加,结肠长度增加,疾病活动指数 (DAI) 降低和组织病理学得分.
- 低血压抑制了促炎性细胞因子 (IL-1β,IL-6,iNOS,TNF-α) 和增加了抗炎性细胞因子 (IL-10) 的表达.
- 通过Nrf2激活,LBP促进了紧结蛋白 (Occludin,ZO-1) 的表达,降低了Claudin-2的表达,增加了有益细菌 (Ruminococcaceae,Lactobacillus,Butyricicoccus,Akkermansia),减少了病原体 (Mucispirillum,Sutterella),并增强了SCFA的产生.
结论:
- 草甘多糖 (LBP) 通过调节炎症反应和加强肠道屏障,有效地减轻DSS诱导的老鼠慢性性结肠炎 (UC).
- LBP通过促进有益的肠道细菌的生长,抑制机会性病原体和增加短链脂肪酸 (SCFA) 生产来表现出益生菌作用.
- 这些发现强调LBP是UC的有希望的治疗剂,通过涉及抗炎症,屏障保护和肠道微生物群调节的机制起作用.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
179
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
179
Drugs for Treatment of Constipation-Predominant IBS
176
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
176
Drugs Affecting GI Tract Motility: Other Laxatives
227
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
227
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
335
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
335
Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
Chronic Bowel Disorders: Introduction
456
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
456


